Placebo News and Research

RSS

Janssen announces CHMP positive opinion for use of paliperidone palmitate 3-monthly injection for schizophrenia treatment

Janssen UK announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the use of paliperidone palmitate 3-monthly injection for the maintenance treatment of schizophrenia in the European Union.

4 Apr 2016

Baricitinib drug shows significant success in treatment of rheumatoid arthritis

In a clinical phase-3-study, an international research cooperation of MedUni Vienna and Stanford University has achieved significant success with the drug Baricitinib for the treatment of rheumatoid arthritis. The test persons exhibited significantly less symptoms of the disorder. The results are now published in the top scientific journal "New England Journal of Medicine".

31 Mar 2016

Researchers aim to improve reliability of future obesity research

Exposing common statistical errors and bias in obesity research to improve the reliability of future research is the aim of the authors of three new papers and a commentary published today in the April issue of Obesity, the scientific journal of The Obesity Society.

30 Mar 2016

FDA proposes to change regulation of ECT treatment

For decades, people with severe depression, bipolar disorder, and other major mental health conditions have gotten help from the treatment known as ECT, when nothing else helped them.

24 Mar 2016

Anticonvulsant medication gabapentin effectively reduces common complication of PONV

The anticonvulsant medication gabapentin—already a useful part of strategies to control pain after surgery—also effectively reduces the common complication of postoperative nausea and vomiting (PONV), reports a study in Anesthesia & Analgesia.

23 Mar 2016

Cinqair (reslizumab) approved for treatment of severe asthma

The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older. Cinqair is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines.

23 Mar 2016

Antipsychotic medications may not be effective in preventing delirium in hospitalized patients

A recent review of the medical literature does not support the use of antipsychotic medications for preventing or treating delirium in hospitalized patients.

23 Mar 2016

Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

On Friday, March 18, the U.S. Food and Drug Administration approved Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs. Anthim is also approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate.

21 Mar 2016

Paracetamol does not meet minimum standard of clinical effectiveness in osteoarthritis patients

In a large-scale analysis of pain-relief medication for osteoarthritis, researchers found that paracetamol does not meet the minimum standard of clinical effectiveness in reducing pain or improving physical function in patients with knee and hip osteoarthritis.

18 Mar 2016

Findings could be final puzzle piece in developing effective dengue vaccine

In a small clinical trial led by the Johns Hopkins Bloomberg School of Public Health, researchers say that a promising single-dose dengue vaccine, developed by scientists at the National Institutes of Health, was 100 percent effective in preventing human volunteers from contracting the virus, the most prevalent mosquito-borne virus in the world.

18 Mar 2016

USF receives $9 million NIH grant to study unique treatment for age-related hearing loss

Researchers in the University of South Florida's Global Center for Hearing and Speech Research, recognized as the world's top research center for age-related hearing loss, have received a five-year, $9 million grant from the National Institutes of Health to study two unique ways to treat age-related hearing loss (ARHL).

17 Mar 2016

Halozyme Therapeutics doses first patient in Halo-301 | Pancreatic study

Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, today announced the first patient has been dosed in its Halo-301 | Pancreatic study, a Phase 3 clinical trial in previously untreated metastatic pancreatic cancer patients.

16 Mar 2016

Could prebiotics benefit early life brain development? An interview with Dr Phil Burnet

Galacto-oligosaccharides are essentially sugar or saccharide molecules that have been joined together into short polymer chains.

16 Mar 2016

Mindfulness meditation reduces pain without endogenous opioid system

Everyone knows that stubbing your toe hurts. What makes it stop hurting is the body's main pain-blocking process - the natural production of opioids.

16 Mar 2016

Omega-3 fatty acids improve cognitive function in older adults

Changes in cognitive function and memory decline form a normal part of aging. However, in neurodegenerative diseases such as Alzheimer's disease or mild cognitive impairment (the pre-dementia phase of Alzheimer's disease), these changes occur more quickly. There are currently no effective treatments for these diseases.

16 Mar 2016

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe.

15 Mar 2016

ZYTIGA plus prednisone provides overall survival benefit in men with early and less aggressive mCRPC

Janssen-Cilag International NV today announced that data from a post-hoc analysis of the Phase 3 COU-AA-302 trial showed that ZYTIGA (abiraterone acetate) plus prednisone provided an 11.8 months overall survival (OS) benefit (53.6 months vs 41.8 months; HR = 0.61 [95% CI, 0.43-0.87]; p = 0.0055), compared to an active control of placebo plus prednisone, in men with early and less aggressive chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

15 Mar 2016

BioSpecifics reports net income of $2.7 million for fourth quarter 2015

BioSpecifics Technologies Corp., a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX in the U.S. and Xiapex in Europe, today announced its financial results for the fourth quarter and full year ended December 31, 2015 and provided a corporate update.

14 Mar 2016

Blueberries can have a real benefit in lowering risk of heart disease, cancer and Alzheimer's

The blueberry, already labeled a "super fruit" for its power to potentially lower the risk of heart disease and cancer, also could be another weapon in the war against Alzheimer's disease. New research being presented today further bolsters this idea, which is being tested by many teams.

14 Mar 2016

Research findings could help treat people with sexual disorders

Undesirable associations with sex can be unlearned, but return if the circumstances change. They must therefore be unlearned in different situations. The drug D-cycloserine may help here. These are the findings of psychologist Mirte Brom.

11 Mar 2016

Placebo News and Research

Janssen announces CHMP positive opinion for use of paliperidone palmitate 3-monthly injection for schizophrenia treatment

Baricitinib drug shows significant success in treatment of rheumatoid arthritis

Researchers aim to improve reliability of future obesity research

FDA proposes to change regulation of ECT treatment

Anticonvulsant medication gabapentin effectively reduces common complication of PONV

Cinqair (reslizumab) approved for treatment of severe asthma

Antipsychotic medications may not be effective in preventing delirium in hospitalized patients

Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

Paracetamol does not meet minimum standard of clinical effectiveness in osteoarthritis patients

Findings could be final puzzle piece in developing effective dengue vaccine

USF receives $9 million NIH grant to study unique treatment for age-related hearing loss

Halozyme Therapeutics doses first patient in Halo-301 | Pancreatic study

Could prebiotics benefit early life brain development? An interview with Dr Phil Burnet

Mindfulness meditation reduces pain without endogenous opioid system

Omega-3 fatty acids improve cognitive function in older adults

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

ZYTIGA plus prednisone provides overall survival benefit in men with early and less aggressive mCRPC

BioSpecifics reports net income of $2.7 million for fourth quarter 2015

Blueberries can have a real benefit in lowering risk of heart disease, cancer and Alzheimer's

Research findings could help treat people with sexual disorders

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News